Skip to main content
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1970 Aug;46(538):537–540. doi: 10.1136/pgmj.46.538.537

The treatment of sarcoidosis

Harold L Israel
PMCID: PMC2467282  PMID: 4921221

Abstract

A discouraging conclusion to many years of study of the natural history of sarcoidosis is the realization that the proper word for the course of sarcoidosis is ‘unpredictable’. An impressive lesson of a controlled study was the frequency with which unexpected and dramatic improvement occurred in the placebo group. Although patients with pulmonary infiltration, uveitis and cutaneous sarcoid have a worse prognosis than the asymptomatic patient with hilar adenopathy, many patients in the former category will recover and some in the latter will go on to death.

A trial of prednisone therapy in a small number of patients with disease restricted to the mediastinal and hilar nodes (Stage I) suggests that prednisone treatment in this form of sarcoidosis may minimize dissemination and progression. An extended trial in Stage I sarcoidosis appears warranted. In more disseminated forms of the disease, the effects of corticosteroids seem to be merely palliative: there is no persuasive evidence that their use in pulmonary sarcoidosis averts fibrosis.

Occasionally corticosteroid therapy is contraindicated, poorly tolerated, or ineffective. In such circumstances chlorambucil or methotrexate may be given a trial. It is clear that both drugs exert an antiinflammatory action similar to that of the corticosteroids; in a few instances these agents appear to surpass corticosteroids in effectiveness.

Full text

PDF
538

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Hoyle C., Smyllie H., Leak D. Prolonged treatment of pulmonary sarcoidosis with corticosteroids. Thorax. 1967 Nov;22(6):519–524. doi: 10.1136/thx.22.6.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. ISRAEL H. L., SONES M., HARRELL D. Cortisone treatment of sarcoidosis: experience with thirty-six cases. J Am Med Assoc. 1954 Oct 2;156(5):461–466. doi: 10.1001/jama.1954.02950050001001. [DOI] [PubMed] [Google Scholar]
  3. SONES M., ISRAEL H. L. Course and prognosis of sarcoidosis. Am J Med. 1960 Jul;29:84–93. doi: 10.1016/0002-9343(60)90009-7. [DOI] [PubMed] [Google Scholar]
  4. Sharma O. P., Colp C., Williams M. H., Jr Course of pulmonary sarcoidosis with and without corticosteriod therapy as determined by pulmonary function studies. Am J Med. 1966 Oct;41(4):541–551. doi: 10.1016/0002-9343(66)90216-6. [DOI] [PubMed] [Google Scholar]
  5. Siltzbach L. E. Sarcoidosis: clinical features and management. Med Clin North Am. 1967 Mar;51(2):483–502. doi: 10.1016/s0025-7125(16)33069-3. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES